EGFR and non-small cell lung carcinoma: According to the above findings, Vβ5-6Jβ2-1 and Vβ20-1Jβ2-1 were both significantly associated with favorable OS and DFS, and Vβ24-1Jβ2-1 and Vβ29-1Jβ2-7 only correlated with favorable OS but not with DFS in patients with stage II/III NSCLC with an EGFR mutation regardless of adjuvant gefitinib or chemotherapy.